Summary:
- Vivoryon Therapeutics, a biopharmaceutical company, has reported its financial results for the first quarter of 2023.
- The company is focused on developing innovative small molecule drugs to treat Alzheimer's disease and other neurodegenerative disorders.
- The report highlights the company's progress in its clinical trials and its financial position, which will help it continue its research and development efforts.